Session date: 
Tuesday, April 12, 2016 - 1:30pm to 2:30pm
Location: 
ISTH Webinar Library Once a Month
Carrboro, NC 27510
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

Through its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars.

Mark Crowther, Peter Verhamme and Jerrold Levy recently participated in the development of an ISTH Guidance document on the reversal of DOACS. Bringing their research to an ISTH Academy webinar, they will give an overview of the results. Verhamme will discuss "Idarucizumab" and Crowther will discuss "Andexanet". Levy will moderate the session and the Q&A at the end of the presentation.

Speakers:
Peter Verhamme "Idarucizumab"
Mark Crowther "Andexanet"
 
Moderator:
Jerrold Levy
 
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
More information and online registration:  http://academy.isth.org/ 
 

This meeting is being supported by Boehringer Ingelheim & Portola Pharmaceuticals


 
Target audience: 

Physician, trainees, fellows and health care professionals managing patients being treated with DOACs

Learning objectives: 

At the conclusion of this activity, I will be able to:

  • Understand current practices for reversing Xa inhibitors
  • Manage emergencies (serious bleeding, urgent surgery) while on dabigatran
  • Understand the mode of action of idarucizucmab, the specific reversal agent of dabigatran
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
Yukio Ozaki
 
Speakers:
Peter Verhamme "Idarucizumab"
Mark Crowther "Andexanet"
Moderator:
Jerrold Levy
 
 
 
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 

Name

Company

Role

Geoffrey Barnes, MDPortolaConsulting
 Blue Cross Blue Shield of MichiganResearch
 BMS/PfizerResearch
Chris Ward, PhDBayerSpeaker
 Boehringer-IngelheimSpeaker, Advisory Board
 BMS/PfizerSpeaker, Advisory Board
Jerrold Levy, MDBI, CSL Behring, JanssenSteering Committee
Peter VerhammeBoehringer, Portola, BayerInvestigator, Advisory Board, Speaker
Yukio OzakiThe Sysmex CorporationAdvisory Board
Mark CrowtherSee Attachment/sites/ocpe.mcw.edu/files/users/65/M.%20Crowther%20Disclosures.pdf

 
 
In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

CME Coordinator Contact Information

Name: 
Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807